Compare QUIK & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUIK | ZNTL |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.2M | 289.0M |
| IPO Year | 1997 | 2020 |
| Metric | QUIK | ZNTL |
|---|---|---|
| Price | $15.67 | $4.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $11.00 | $6.60 |
| AVG Volume (30 Days) | 479.1K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,112,000.00 | N/A |
| Revenue This Year | $75.17 | N/A |
| Revenue Next Year | $16.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.80 | $1.21 |
| 52 Week High | $24.33 | $6.95 |
| Indicator | QUIK | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 64.59 |
| Support Level | $6.10 | $3.53 |
| Resistance Level | $23.39 | $5.11 |
| Average True Range (ATR) | 1.61 | 0.38 |
| MACD | -0.64 | 0.11 |
| Stochastic Oscillator | 14.29 | 81.88 |
QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.